OUP user menu

Journal of Crohn's and Colitis: 9 (8)

Editor-in-Chief

Laurence J. Egan, Ireland

Associate Editors

Maria T. Abreu, USAShomron Ben-Horin, IsraelSilvio Danese, ItalyPeter Lakatos, HungaryMiles Parkes, UKGijs van den Brink, NLSéverine Vermeire, Belgium

6.234
5.425

Published on behalf of

Appropriateness of therapy for active Crohn's disease: Results of a multidisciplinary international expert panel—EPACT II

Pierre Michetti, Marc Stelle, Pascal Juillerat, Miquel Gassull, Franz Josef Heil, Eduard Stange, Christian Mottet, Jean-Jacques Gonvers, Valérie Pittet, John-Paul Vader, Florian Froehlich, Christian Felley,
DOI: http://dx.doi.org/10.1016/j.crohns.2009.05.003 232-240 First published online: 1 December 2009

Abstract

The increasing number of trials testing management strategies for luminal Crohn's disease (CD) has not filled all the gaps in our knowledge and thus, in clinical practice, many decisions for CD patients have to be taken without the benefit of high-quality evidence.

Methods: A multidisciplinary European expert panel used the RAND Appropriateness Method to develop and rate explicit criteria for the management of individual patients with active, steroid-dependent (ST-D) and steroid-refractory (ST-R) CD.

Results: Overall, 296 indications pertaining to mild-to-moderate, severe, ST-D, and ST-R CD were rated. In anti-TNF naïve patients, budesonide and prednisone were found to be appropriate for mild-moderate CD, and infliximab (IFX) was appropriate when these had previously failed or had not been tolerated. In patients with a prior successful treatment by IFX, this drug, with or without co-administration of a thiopurine analog, was favoured. Other anti-TNFs were appropriate in the presence of intolerance or resistance to IFX. High-dose steroids, IFX or adalimumab were appropriate in severe active CD. For the 105 indications for ST-D or ST-R disease, the panel considered the thiopurine analogs, methotrexate, IFX, adalimumab, and surgery for limited resection, to be appropriate, depending on the outcome of prior therapies. Anti-TNFs were generally considered appropriate in ST-R.

Conclusion: Steroids, including budesonide for mild-to-moderate CD, remain the first-line therapy for active luminal CD. Anti-TNFs, in particular IFX as shown by the amount of available evidence, remain the second-line therapy for most indications. Thiopurine analogs, methotrexate and anti-TNFs are favoured in ST-D patients and ST-R patients.

Keywords
  • Crohn's Disease
  • Therapy
  • Steroids
  • Azathioprine
  • Methotrexate
  • Anti-TNF
  • Pegol
View Full Text

Log in through your institution